Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Smith

Showing results (541-550 of 594) with videos related to

Pageof 60
Sort By:
Journal of the American Academy of Dermatology|December 7, 2014
Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in MinnesotaJerry D Brewer, Tait D Shanafelt, Farzaneh Khezri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialOlayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Human Molecular Genetics|September 13, 2015
miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivoPascal Y Smith, Julia Hernandez-Rapp, Francis Jolivette, et al.
NPJ Digital Medicine|March 19, 2024
Effect of clinical decision support for severe hypercholesterolemia on low-density lipoprotein cholesterol levelsHana Bangash, Seyedmohammad Saadatagah, Mohammadreza Naderian, et al.
Metabolites|July 26, 2024
A Multiomics, Molecular Atlas of Breast Cancer SurvivorsBrent A Bauer, Caleb M Schmidt, Kathryn J Ruddy, et al.
Annals of Neurology|January 3, 2018
Autoimmune encephalitis epidemiology and a comparison to infectious encephalitisDivyanshu Dubey, Sean J Pittock, Cecilia R Kelly, et al.
Cells|January 28, 2026
Network Hypoactivity in ALG13-CDG: Disrupted Developmental Pathways and E/I Imbalance as Early Drivers of Neurological Features in CDGRameen Shah, Rohit Budhhraja, Silvia Radenkovic, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
ALG13 loss-of-function alters glycosylation, impairs neuronal maturation, and drives network hypoactivity in a cortical organoid model of CDGRameen Shah, Rohit Budhraja, Silvia Radenkovic, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Pageof 60

Showing results (541-550 of 594) with videos related to

Sort By:
Pageof 60
Journal of the American Academy of Dermatology|December 7, 2014
Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: a Rochester Epidemiology Project population-based study in MinnesotaJerry D Brewer, Tait D Shanafelt, Farzaneh Khezri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 18, 2020
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical TrialsJean van Wyk, Chloe Orkin, Rafael Rubio, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2022
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized TrialOlayemi Osiyemi, Stéphane De Wit, Faïza Ajana, et al.
Human Molecular Genetics|September 13, 2015
miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivoPascal Y Smith, Julia Hernandez-Rapp, Francis Jolivette, et al.
NPJ Digital Medicine|March 19, 2024
Effect of clinical decision support for severe hypercholesterolemia on low-density lipoprotein cholesterol levelsHana Bangash, Seyedmohammad Saadatagah, Mohammadreza Naderian, et al.
Metabolites|July 26, 2024
A Multiomics, Molecular Atlas of Breast Cancer SurvivorsBrent A Bauer, Caleb M Schmidt, Kathryn J Ruddy, et al.
Annals of Neurology|January 3, 2018
Autoimmune encephalitis epidemiology and a comparison to infectious encephalitisDivyanshu Dubey, Sean J Pittock, Cecilia R Kelly, et al.
Cells|January 28, 2026
Network Hypoactivity in ALG13-CDG: Disrupted Developmental Pathways and E/I Imbalance as Early Drivers of Neurological Features in CDGRameen Shah, Rohit Budhhraja, Silvia Radenkovic, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
ALG13 loss-of-function alters glycosylation, impairs neuronal maturation, and drives network hypoactivity in a cortical organoid model of CDGRameen Shah, Rohit Budhraja, Silvia Radenkovic, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 25, 2020
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled AnalysisJoseph Eron, Chien-Ching Hung, Jean-Guy Baril, et al.
Pageof 60